XML 55 R44.htm IDEA: XBRL DOCUMENT v3.20.2
SEGMENTS AND GEOGRAPHIC REGIONS (Tables)
 9 Months Ended
Sep. 30, 2020
Segment Reporting Information [Line Items]  
Schedule of Operating Segment Information
Segment InformationElect. & ImagingNutrition & BiosciencesTransp. & IndustrialSafety & Const.Non-CoreCorp.Total
In millions
Three months ended September 30, 2020
Net sales$1,004 $1,467 $1,045 $1,249 $331 $— $5,096 
Operating EBITDA 1
$357 $379 $242 $324 $14 $(16)$1,300 
Equity in earnings of nonconsolidated affiliates
$8 $1 $1 $7 $13 $— $30 
Three months ended September 30, 2019
Net sales$934 $1,525 $1,209 $1,327 $431 $— $5,426 
Operating EBITDA 1
$320 $354 $306 $352 $94 $(25)$1,401 
Equity in earnings of nonconsolidated affiliates 2
$10 $— $1 $7 $26 $— $44 
Nine months ended September 30, 2020
Net sales$2,793 $4,557 $3,021 $3,769 $1,005 $— $15,145 
Operating EBITDA 1
$887 $1,182 $599 $1,041 $149 $(102)$3,756 
Equity in earnings of nonconsolidated affiliates
$27 $2 $3 $19 $121 $— $172 
Nine months ended September 30, 2019
Net sales$2,617 $4,618 $3,795 $3,951 $1,327 $— $16,308 
Pro forma operating EBITDA 1
$854 $1,089 $1,036 $1,108 $296 $(130)$4,253 
Equity in earnings of nonconsolidated affiliates 2
$18 $— $3 $22 $92 $— $135 
Reconciliation of Income from Continuing Operations, net of tax to Operating EBITDA
Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Three Months Ended September 30, 2020 and 2019Three Months Ended September 30,
In millions20202019
Loss (income) from continuing operations, net of tax $(72)$372 
+ Provision for income taxes on continuing operations92 78 
Income from continuing operations before income taxes$20 $450 
+ Depreciation and amortization780 499 
- Interest income 1
3 1 
+ Interest expense 2
165 177 
- Non-operating pension/OPEB benefit 1
5 21 
- Foreign exchange losses, net 1
(10)(23)
- Significant items 3
(333)(274)
Operating EBITDA$1,300 $1,401 
1. Included in "Sundry income (expense) - net."
2. The three months ended September 30, 2020 excludes N&B financing activity. Refer to details of significant items below.
3. The significant items for the three months ended September 30, 2020 and 2019 are presented on an as reported basis.
Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Nine Months Ended September 30, 2020 and 2019Nine Months Ended September 30,
In millions20202019
Loss from continuing operations, net of tax $(3,153)$(805)
+ Provision for income taxes on continuing operations100 142 
Loss from continuing operations before income taxes$(3,053)$(663)
+ Pro forma adjustments 1
— 122 
+ Depreciation and amortization2,326 1,533 
- Interest income 2
7 50 
+ Interest expense 3
519 522 
- Non-operating pension/OPEB benefit 2
24 60 
- Foreign exchange losses, net 2
(41)(101)
+ Costs historically allocated to the materials science and agriculture businesses 4
— 256 
- Significant items 5
(3,954)(2,492)
Operating EBITDA 1
$3,756 $4,253 
1. For the nine months ended September 30, 2019, operating EBITDA is on a pro forma basis. The pro forma adjustment reflects the net pro forma impact of items directly attributable to the Transactions, as applicable.
2. Included in "Sundry income (expense) - net."
3. The nine months ended September 30, 2020 excludes N&B financing activity. Refer to details of significant items below.
4. Costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205.
5. The significant items for the nine months ended September 30, 2020 are presented on an as reported basis. The significant items for the nine months ended September 30, 2019 are presented on a pro forma basis.
Schedule of Certain Items by Segment The following tables summarize the pre-tax impact of significant items by segment that are excluded from Operating EBITDA and pro forma Operating EBITDA above:
Significant Items by Segment for the Three Months Ended September 30, 2020Elect. & ImagingNutrition & BiosciencesTransp. & IndustrialSafety & ConstructionNon-CoreCorporateTotal
In millions
Integration and separation costs 1
$— $— $— $— $— $(127)$(127)
Restructuring and asset related credits (charges) - net 2
(1)(5)— (2)(1)(5)(14)
Goodwill impairment charges 3
— — — — (183)— (183)
Asset impairment charges 3, 4
— — — — (370)— (370)
Gain on divestitures 5
— — — — 393 — 393 
N&B financing activity - net 6
— — — — — (32)(32)
Total$(1)$(5)$— $(2)$(161)$(164)$(333)
1. Integration and separation costs related to the post-DWDP Merger integration and the intended separation of the N&B Business.
2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.
3. Refer to Note 11 for additional information.
4. Refer to Note 5 for additional information.
5. Refer to Note 3 for additional information.
6. Represents interest expense, net related to the N&B Notes as well as the financing fee amortization related to the intended separation of the N&B Business.
Significant Items by Segment for the Three Months Ended September 30, 2019Elect. & ImagingNutrition & BiosciencesTransp. & IndustrialSafety & ConstructionNon-CoreCorporateTotal
In millions
Integration and separation costs 1
$— $— $— $— $— $(191)$(191)
Restructuring and asset related charges - net 2
(35)(7)(6)(5)(2)(28)(83)
Total$(35)$(7)$(6)$(5)$(2)$(219)$(274)
1.Integration and separation costs related to post-DWDP Merger integration and business separation activities.
2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.
Significant Items by Segment for the Nine Months Ended September 30, 2020Elect. & ImagingNutrition & BiosciencesTransp. & IndustrialSafety & ConstructionNon-CoreCorporateTotal
In millions
Integration and separation costs 1
$— $— $— $— $— $(469)$(469)
Restructuring and asset related charges - net 2
(2)(9)(15)(15)(1)(104)(146)
Goodwill impairment charges 3
— — (2,498)— (716)— (3,214)
Asset impairment charges 3, 4
— — (21)— (640)— (661)
Gain on divestitures 5
197 — — — 393 — 590 
N&B financing activity - net 6
— — — — — (54)(54)
Total$195 $(9)$(2,534)$(15)$(964)$(627)$(3,954)
1. Integration and separation costs related to the post-DWDP Merger integration and the intended separation of the N&B Business.
2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.
3. Refer to Note 11 for additional information.
4. Refer to Note 5 for additional information.
5. Refer to Note 3 for additional information.
6. Represents interest expense, net related to the N&B Notes as well as the financing fee amortization related to the intended separation of the N&B Business.

Significant Items by Segment for the Nine Months Ended September 30, 2019
(Pro Forma)		Elect. & ImagingNutrition & BiosciencesTransp. & IndustrialSafety & ConstructionNon-CoreCorporateTotal
In millions
Integration and separation costs 1
$— $— $— $— $— $(976)$(976)
Restructuring and asset related charges - net 2
(42)(56)(18)(27)(2)(85)(230)
Goodwill impairment charges 3
— (933)— — (242)— (1,175)
Asset impairment charges 4
— (63)— — — — (63)
Income tax relates item 5
— — — (48)— — (48)
Total$(42)$(1,052)$(18)$(75)$(244)$(1,061)$(2,492)
1.Integration and separation costs related to the DWDP Merger, post-DWDP Merger integration and business separation activities.
2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.
3. Refer to Note 11 for additional information.
4. Refer to Note 5 for additional information.
5. Charge included in "Sundry income (expense) - net" which reflects a reduction in gross proceeds from lower withholding taxes related to a prior year legal settlement.